Yao Qin, Zhang Xinyue, Huang Yueping, Wang Hao, Hui Xin, Zhao Baixiao
Beijing University of Chinese Medicine, Beijing, China.
Medicine (Baltimore). 2019 Nov;98(48):e18209. doi: 10.1097/MD.0000000000018209.
Hyperlipidemia has been a root cause of atherosclerosis, which leads to a high risk to serious cardio-cerebrovascular disease. Many trials have reported that moxibustion therapy is effective in lowering blood lipid levels when treating hyperlipidemia. The aim of this systematic review is to assess the effectiveness and safety of moxibustion therapy for hyperlipidemia.
Two reviewers will electronically search the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; China National Knowledge Infrastructure (CNKI); Chinese Biomedical Literature Database (CBM); Chinese Scientific Journal Database (VIP database); and Wan-Fang Database from the inception, without restriction of publication status and languages. Additional searching including researches in progress, the reference lists and the citation lists of identified publications. Study selection, data extraction, and assessment of study quality will be performed independently by 2 reviewers. Changes of blood lipid levels from baseline to the end of the treatment, including low-density lipoprotein cholesterol (LDL-C) level, total cholesterol (TC) level, triglycerides (TG) level and high-density lipoprotein cholesterol (HDL-C) level will be assessed as the primary outcomes. Quality of life, long-term effect and safety will be evaluated as secondary outcomes. If it is appropriate for a meta-analysis, RevMan 5.3 statistical software will be used; otherwise, a descriptive analysis will be conducted. Data will be synthesized by either the fixed-effects or random-effects model according to a heterogeneity test. The results will be presented as risk ratio (RR) with 95% confidence intervals (CIs) for dichotomous data and weight mean difference (WMD) or standard mean difference (SMD) 95% CIs for continuous data.
This study will provide a comprehensive review of the available evidence for the treatment of moxibustion with hyperlipidemia.
The conclusions of our study will provide an evidence to judge whether moxibustion is an effective and safe intervention for patients with hyperlipidemia.
This systematic review will be disseminated in a peer-reviewed journal or presented at relevant conferences. It is not necessary for a formal ethical approval because the data are not individualized.
PROSPERO CRD42019130545.
高脂血症一直是动脉粥样硬化的根本原因，而动脉粥样硬化会导致严重的心脑血管疾病风险增加。许多试验报告称，艾灸疗法在治疗高脂血症时可有效降低血脂水平。本系统评价的目的是评估艾灸疗法治疗高脂血症的有效性和安全性。
两名评价员将通过电子检索以下数据库：Cochrane对照试验中心注册库（CENTRAL）；PubMed；EMBASE；中国知网（CNKI）；中国生物医学文献数据库（CBM）；中文科技期刊数据库（维普数据库）；以及万方数据库，检索时间从建库开始，不受出版状态和语言限制。额外检索包括正在进行的研究、已识别出版物的参考文献列表和被引文献列表。研究选择、数据提取和研究质量评估将由两名评价员独立进行。从基线到治疗结束时血脂水平的变化，包括低密度脂蛋白胆固醇（LDL-C）水平、总胆固醇（TC）水平、甘油三酯（TG）水平和高密度脂蛋白胆固醇（HDL-C）水平将作为主要结局进行评估。生活质量、长期疗效和安全性将作为次要结局进行评估。如果适合进行荟萃分析，将使用RevMan 5.3统计软件；否则，将进行描述性分析。将根据异质性检验采用固定效应模型或随机效应模型对数据进行综合分析。结果将以风险比（RR）及95%置信区间（CI）表示二分数据，以加权均数差（WMD）或标准化均数差（SMD）及95%CI表示连续数据。
本研究将对艾灸治疗高脂血症的现有证据进行全面综述。
我们研究的结论将为判断艾灸是否是高脂血症患者有效且安全的干预措施提供证据。
本系统评价将在同行评审期刊上发表或在相关会议上展示。由于数据并非个体化数据，无需正式伦理批准。
PROSPERO CRD42019130545。
